Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.
Saved in:
| Title: | Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial. |
|---|---|
| Authors: | Lehmann BD; Department of Medicine, Vanderbilt University, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee., Abramson VG; Department of Medicine, Vanderbilt University, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee., Dees EC; Department of Medicine and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill., Shah PD; Department of Medicine, University of Pennsylvania, Philadelphia., Ballinger TJ; Department of Medicine, Indiana University, Indianapolis., Isaacs C; Department of Medical Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC., Santa-Maria CA; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland., An H; Department of Otolaryngology, Vanderbilt University Medical Center, Nashville, Tennessee., Gonzalez-Ericsson PI; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee.; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, Tennessee., Sanders ME; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee.; Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee., Newsom KC; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee., Abramson RG; Department of Biomedical Engineering, Vanderbilt University School of Engineering, Nashville, Tennessee., Sheng Q; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.; Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee., Hsu CY; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.; Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee., Shyr Y; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.; Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee., Wolff AC; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland., Pietenpol JA; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee.; Department of Biochemistry, Vanderbilt University, Nashville, Tennessee. |
| Source: | JAMA oncology [JAMA Oncol] 2024 Feb 01; Vol. 10 (2), pp. 193-201. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38095878 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Lehmann+BD%22">Lehmann BD</searchLink>; Department of Medicine, Vanderbilt University, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee.<br /><searchLink fieldCode="AU" term="%22Abramson+VG%22">Abramson VG</searchLink>; Department of Medicine, Vanderbilt University, Nashville, Tennessee.; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee.<br /><searchLink fieldCode="AU" term="%22Dees+EC%22">Dees EC</searchLink>; Department of Medicine and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill.<br /><searchLink fieldCode="AU" term="%22Shah+PD%22">Shah PD</searchLink>; Department of Medicine, University of Pennsylvania, Philadelphia.<br /><searchLink fieldCode="AU" term="%22Ballinger+TJ%22">Ballinger TJ</searchLink>; Department of Medicine, Indiana University, Indianapolis.<br /><searchLink fieldCode="AU" term="%22Isaacs+C%22">Isaacs C</searchLink>; Department of Medical Oncology, Lombardi Cancer Center, Georgetown University, Washington, DC.<br /><searchLink fieldCode="AU" term="%22Santa-Maria+CA%22">Santa-Maria CA</searchLink>; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.<br /><searchLink fieldCode="AU" term="%22An+H%22">An H</searchLink>; Department of Otolaryngology, Vanderbilt University Medical Center, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Gonzalez-Ericsson+PI%22">Gonzalez-Ericsson PI</searchLink>; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee.; Breast Cancer Research Program, Vanderbilt University Medical Center, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Sanders+ME%22">Sanders ME</searchLink>; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee.; Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Newsom+KC%22">Newsom KC</searchLink>; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee.<br /><searchLink fieldCode="AU" term="%22Abramson+RG%22">Abramson RG</searchLink>; Department of Biomedical Engineering, Vanderbilt University School of Engineering, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Sheng+Q%22">Sheng Q</searchLink>; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.; Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Hsu+CY%22">Hsu CY</searchLink>; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.; Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Shyr+Y%22">Shyr Y</searchLink>; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.; Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Wolff+AC%22">Wolff AC</searchLink>; Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.<br /><searchLink fieldCode="AU" term="%22Pietenpol+JA%22">Pietenpol JA</searchLink>; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Tennessee.; Department of Biochemistry, Vanderbilt University, Nashville, Tennessee. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101652861%22">JAMA oncology</searchLink> [JAMA Oncol] 2024 Feb 01; Vol. 10 (2), pp. 193-201. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Medical+Association%22">American Medical Association </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101652861 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2374-2445 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223742437%22">23742437 </searchLink><i>NLM ISO Abbreviation: </i>JAMA Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38095878 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1001/jamaoncol.2023.5424 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 193 Titles: – TitleFull: Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Lehmann BD – PersonEntity: Name: NameFull: Abramson VG – PersonEntity: Name: NameFull: Dees EC – PersonEntity: Name: NameFull: Shah PD – PersonEntity: Name: NameFull: Ballinger TJ – PersonEntity: Name: NameFull: Isaacs C – PersonEntity: Name: NameFull: Santa-Maria CA – PersonEntity: Name: NameFull: An H – PersonEntity: Name: NameFull: Gonzalez-Ericsson PI – PersonEntity: Name: NameFull: Sanders ME – PersonEntity: Name: NameFull: Newsom KC – PersonEntity: Name: NameFull: Abramson RG – PersonEntity: Name: NameFull: Sheng Q – PersonEntity: Name: NameFull: Hsu CY – PersonEntity: Name: NameFull: Shyr Y – PersonEntity: Name: NameFull: Wolff AC – PersonEntity: Name: NameFull: Pietenpol JA IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: 2024 Feb 01 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2374-2445 Numbering: – Type: volume Value: 10 – Type: issue Value: 2 Titles: – TitleFull: JAMA oncology Type: main |
| ResultId | 1 |
